Plain-English translation of NCT07392541 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment combination for people with advanced bile duct cancer that cannot be surgically removed. The combination includes , a newer immunotherapy drug, along with two standard chemotherapy medications (gemcitabine and cisplatin) and simvastatin, a medication that may help the cancer treatment work better. Researchers want to see if this four-drug approach is safe and whether it can shrink tumors and slow cancer growth.
Bile duct cancer is difficult to treat, especially when it has already spread or grown beyond the bile ducts. This trial is exploring whether combining this newer immunotherapy with proven chemotherapy drugs might offer patients a more effective option than current standard treatments alone.
You likely qualify if…
You likely don't qualify if…
You would receive the four-drug combination over 8 treatment cycles, with each cycle lasting 21 days. After the initial 8 cycles, if the treatment is working and you tolerate it well, you would continue taking the medication as maintenance therapy to keep the cancer from growing. Throughout the study, you would have regular clinic visits, blood tests, and imaging scans (like CT scans) to monitor how well the cancer is responding and to watch for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China